Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy.

PURPOSE Ambulatory chemotherapy is patient friendly but may result in toxicity-induced unscheduled hospitalizations (TIUHs). This emerging issue may increase health care costs. We studied the cost effectiveness of a hospital-home monitoring program based on systematic iterative telephone calls after chemotherapy. PATIENTS AND METHODS We retrospectively evaluated the rates of chemotherapy-induced unscheduled hospitalizations in patients who were treated in August 2008. Patients were contacted by telephone 1 day before chemotherapy and on the second and eighth days after undergoing chemotherapy. Costs associated with TIUHs were calculated and compared with those of a cohort concomitantly treated using the standard follow-up procedure. RESULTS A total of 259 patients entered the hospital-home monitoring program. They were compared with 86 patients who had similar characteristics but underwent the standard treatment and follow-up procedure. Inclusion in the hospital-home monitoring program resulted in patients experiencing TIUHs approximately half as frequently as patients in the other group (2.4% v 4.9%; P < .01). Patients in the program experienced TIUHs for a median length of stay of 4 days, representing a nonsignificant reduction in duration of hospitalization (P not significant). Consequently, through a two-fold reduction in TIUH annual incidence, this program represents a reduction in unscheduled hospitalizations per year of 383 days, decreasing hospital costs by €201.468 ($292,468) per year. CONCLUSION The hospital-home monitoring program is a cost-effective strategy for offering ambulatory chemotherapy treatment to patients with cancer. This program has become our standard procedure for ambulatory chemotherapy in patients with cancer.

[1]  K. Kerr,et al.  The impact of follow-up telephone calls to patients after hospitalization. , 2001, Disease-a-month : DM.

[2]  J. Hay,et al.  Economic Burden of Haematological Adverse Effects in Cancer Patients , 2007, Clinical drug investigation.

[3]  J. D'Amore,et al.  Does telephone follow-up predict patient satisfaction and readmission? , 2011, Population health management.

[4]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[5]  C. Peschel,et al.  Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer , 2011, Oncology Research and Treatment.

[6]  G. Lyman,et al.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.

[7]  C. Bennett,et al.  Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. , 2007, The oncologist.

[8]  K. Olsen.  Patient complexity and GPs' income under mixed remuneration. , 2012, Health economics.

[9]  B. Riegel,et al.  Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. , 2002, Archives of internal medicine.

[10]  Quint Studer.  How Healthcare Wins with Consumers Who Want More , 2003, Frontiers of Health Services Management.

[11]  A. Bottomley,et al.  Treatment satisfaction as an outcome measure in cancer clinical treatment trials , 2002, Expert review of pharmacoeconomics & outcomes research.

[12]  Bertrand Knebelmann,et al.  An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. , 2011, The oncologist.

[13]  G. Peterson.  Practical utility of case-management telephone intervention in heart failure? , 2002, Archives of internal medicine.

[14]  J. Bonneterre,et al.  Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.